MDVN up +1.29% percent Today $MDVN High is at 108.18 and the Low 106.24 with current volume of 91,872.
Recent News posted below.
Medivation Inc MDVN other info.
http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Should Johnson & Johnson Buy Medivation Inc.?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 6:55AM CST
Source: Johnson & Johnson. Johnson & Johnson is losing the battle for prostate cancer market share to the far smaller Medivation , but that may not mean that J&J should step up and acquire the company. First, a little...
MDVN: 107.56 (+0.66), JNJ: 108.25 (+0.09)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.56 (+0.66), AGN: 210.83 (+12.18), JNJ: 108.25 (+0.09), DNDN: 0.13 (+0.02)
Update: Medivation Q3 Earnings
ONeil Trader - at Seeking Alpha - Tue Nov 11, 7:13AM CST
MDVN: 107.56 (+0.66)
Uptrend Call Working As Medivation Stock Rises 15.2% (MDVN)
Comtex SmarTrend(R) - Mon Nov 10, 9:38AM CST
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on October 21st, 2014 at $96.87. In approximately 3 weeks, Medivation has returned 15.20% as of today's recent price of $111.60.
MDVN: 107.56 (+0.66)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.56 (+0.66), ABMD: 33.22 (-0.03), JNJ: 108.25 (+0.09), AMGN: 159.19 (+1.51), EXAS: 23.06 (+0.06), ARAY: 6.96 (-0.06), HOLX: 26.34 (+0.04), PBYI: 221.13 (+4.91)
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy
at The Street - Mon Nov 10, 6:12AM CST
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
MDVN: 107.51 (+0.61), JNJ: 108.25 (+0.09), DNDN: 0.13 (+0.02)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 107.51 (+0.61), JNJ: 108.25 (+0.09), BIIB: 306.04 (+0.61), PTLA: 27.03 (+0.46), GILD: 101.12 (-0.94), CELG: 104.85 (+0.80)
Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 107.51 (+0.61)
Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 107.51 (+0.61)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.29 (+0.06), MDVN: 107.51 (+0.61), BIIB: 306.04 (+0.61)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 107.51 (+0.61), AOL: 46.51 (+0.47), AZN: 72.14 (-0.71)
Medivation's (MDVN) CEO David Hung on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:40PM CST
MDVN: 107.51 (+0.61)
Medivation (MDVN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
MDVN: 107.51 (+0.61)
Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 107.51 (+0.61)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 107.51 (+0.61)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.51 (+0.61), ENDP: 67.07 (+0.81), AUXL: 32.30 (+0.13), SHPG: 204.24 (+1.62), DNDN: 0.13 (+0.02), SNSS: 1.91 (+0.24), ABBV: 65.01 (+1.01), SNY: 47.30 (+0.62), MNKD: 6.14 (-0.02), XOMA: 3.98 (+0.06)
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 107.51 (+0.61)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.51 (+0.61), ACT: 248.67 (+4.90), PRGO: 154.63 (+0.17), ALNY: 89.51 (-0.61)
Recent News posted below.
Medivation Inc MDVN other info.
http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Should Johnson & Johnson Buy Medivation Inc.?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 6:55AM CST
Source: Johnson & Johnson. Johnson & Johnson is losing the battle for prostate cancer market share to the far smaller Medivation , but that may not mean that J&J should step up and acquire the company. First, a little...
MDVN: 107.56 (+0.66), JNJ: 108.25 (+0.09)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.56 (+0.66), AGN: 210.83 (+12.18), JNJ: 108.25 (+0.09), DNDN: 0.13 (+0.02)
Update: Medivation Q3 Earnings
ONeil Trader - at Seeking Alpha - Tue Nov 11, 7:13AM CST
MDVN: 107.56 (+0.66)
Uptrend Call Working As Medivation Stock Rises 15.2% (MDVN)
Comtex SmarTrend(R) - Mon Nov 10, 9:38AM CST
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on October 21st, 2014 at $96.87. In approximately 3 weeks, Medivation has returned 15.20% as of today's recent price of $111.60.
MDVN: 107.56 (+0.66)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.56 (+0.66), ABMD: 33.22 (-0.03), JNJ: 108.25 (+0.09), AMGN: 159.19 (+1.51), EXAS: 23.06 (+0.06), ARAY: 6.96 (-0.06), HOLX: 26.34 (+0.04), PBYI: 221.13 (+4.91)
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy
at The Street - Mon Nov 10, 6:12AM CST
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
MDVN: 107.51 (+0.61), JNJ: 108.25 (+0.09), DNDN: 0.13 (+0.02)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 107.51 (+0.61), JNJ: 108.25 (+0.09), BIIB: 306.04 (+0.61), PTLA: 27.03 (+0.46), GILD: 101.12 (-0.94), CELG: 104.85 (+0.80)
Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 107.51 (+0.61)
Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 107.51 (+0.61)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.29 (+0.06), MDVN: 107.51 (+0.61), BIIB: 306.04 (+0.61)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 107.51 (+0.61), AOL: 46.51 (+0.47), AZN: 72.14 (-0.71)
Medivation's (MDVN) CEO David Hung on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:40PM CST
MDVN: 107.51 (+0.61)
Medivation (MDVN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
MDVN: 107.51 (+0.61)
Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 107.51 (+0.61)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 107.51 (+0.61)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.51 (+0.61), ENDP: 67.07 (+0.81), AUXL: 32.30 (+0.13), SHPG: 204.24 (+1.62), DNDN: 0.13 (+0.02), SNSS: 1.91 (+0.24), ABBV: 65.01 (+1.01), SNY: 47.30 (+0.62), MNKD: 6.14 (-0.02), XOMA: 3.98 (+0.06)
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 107.51 (+0.61)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.51 (+0.61), ACT: 248.67 (+4.90), PRGO: 154.63 (+0.17), ALNY: 89.51 (-0.61)
